Eli Lilly hikes Mounjaro prices in the UK
Digest more
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.
4don MSN
If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today
Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has delivered a dividend-adjusted total return of roughly 347% over the last five years. After factoring in the added benefits of the company's dividend, a $1,000 investment made in Eli Lilly stock would now be worth roughly $4,472.
What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction value is $500,472.
Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its investment appeal. Read the full stock analysis here.
Eli Lilly (LLY) recently faced legal challenges as Texas Attorney General Ken Paxton filed a lawsuit against the company, accusing it of bribery and inducement, which might weigh heavily on its reputation.
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications.